Fig. 4From: PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trialsOverall survival of patients with pMMR endometrial cancer treated with PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel chemotherapy-based versus carboplatin plus paclitaxel chemotherapy-basedBack to article page